Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

msh id	COM:INVITAE
symbol	NVTA
name	Invitae Corporation
homepage url	https://www.invitae.com
country	US
sector	Healthcare
industry	Medical - Diagnostics & Research
market	STOCKS
employee count	1.7K
crunchbase url	-
linkedin url	-
founders	-

market cap	5.44M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.01
growth cost of revenue	0.2
growth depreciation and amortization	0.41
growth ebitda	0.16
growth ebitda ratio	0.25
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.22
growth gross profit	-0.11
growth gross profit ratio	-0.21

COM:INVITAE

Invitae Corp.

Last Close

0.03

14/02 20:59

Market Cap

5.44M

Beta: -

Volume Today

22.46M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.23B
cost of revenue	1.23B
depreciation and amortization	150.13M
ebitda	-564.11M
ebitda ratio	-1.09
eps	-13.18
eps diluted	-13.18
operating expenses	813.28M
operating income	-714.24M
operating income ratio	-1.38

accounts receivables	-29.92M
capital expenditure	-53.31M
cash at beginning of period	933.53M
cash at end of period	267.52M
inventory	30.39M
working capital ttm	219.98M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-